Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Pazopanib has been added to the Clinical Practice Guidelines in Oncology for Kidney Cancer, following its US FDA approval last month

    • 14 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      National Comprehensive Cancer Network.NCCN Guidelines for Kidney Cancer Updated to Include Pazopanib for Advanced Disease; Free Webinar Discusses Updates. Media Release: 3 Nov 2009. Available from: URL: http://www.nccn.org

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Pazopanib has been added to the Clinical Practice Guidelines in Oncology for Kidney Cancer, following its US FDA approval last month. Pharmacoecon. Outcomes News 591, 9 (2009). https://doi.org/10.2165/00151234-200905910-00020

    Download citation

    Keywords

    • Tyrosine
    • Tyrosine Kinase
    • Renal Cell Carcinoma
    • Renal Cell
    • Kinase Inhibitor